Telisotuzumab Vedotin
Showing 1 - 25 of 268
NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Telisotuzumab Vedotin
- +4 more
- (no location specified)
Oct 17, 2023
NSCLC (NSCLC) Trial in West Perth, Yau Ma Tei, Petakh Tikva (Telisotuzumab vedotin)
Available
- Non-Small Cell Lung Cancer (NSCLC)
- Telisotuzumab vedotin
-
West Perth, Western Australia, Australia
- +2 more
Feb 24, 2022
Advanced Solid Tumors Cancer Trial in Worldwide (Osimertinib, Nivolumab, Telisotuzumab vedotin)
Recruiting
- Advanced Solid Tumors Cancer
- Osimertinib
- +3 more
-
Scottsdale, Arizona
- +35 more
Jan 12, 2023
Non Small Cell Lung Cancer Trial in Worldwide (Telisotuzumab Vedotin)
Not yet recruiting
- Non Small Cell Lung Cancer
- Telisotuzumab Vedotin
-
Clayton, Victoria, Australia
- +54 more
Aug 23, 2022
Non Small Cell Lung Cancer Trial in Worldwide (Telisotuzumab Vedotin, Docetaxel)
Recruiting
- Non Small Cell Lung Cancer
- Telisotuzumab Vedotin
- Docetaxel
-
Los Angeles, California
- +212 more
Jan 26, 2023
Specific Protein Overexpression in Adult Non-Small Cell Lung
Not yet recruiting
- Non Small Cell Lung Cancer
- (no location specified)
Sep 29, 2023
Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8 Trial in Phoenix,
Not yet recruiting
- Metastatic Penile Squamous Cell Carcinoma
- +3 more
- Enfortumab Vedotin
-
Phoenix, Arizona
- +2 more
Oct 23, 2023
DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial
Not yet recruiting
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- +2 more
- Biospecimen Collection
- +5 more
- (no location specified)
Sep 5, 2023
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Capecitabine, oxaliplatin, Disitamab Vedotin)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Capecitabine
- +3 more
-
Beijing, Beijing, China
- +10 more
Nov 23, 2023
Solid Malignancies Trial (Tisotumab Vedotin)
Not yet recruiting
- Solid Malignancies
- Tisotumab Vedotin
- (no location specified)
May 9, 2023
Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)
Not yet recruiting
- Renal Pelvis and Ureter Urothelial Carcinoma
- Biopsy
- +5 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023
Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Tumor Trial in Atlanta (procedure,
Not yet recruiting
- Bladder Squamous Cell Carcinoma
- +10 more
- Biospecimen Collection
- +5 more
-
Atlanta, Georgia
- +3 more
Feb 20, 2023
Breast Cancer Trial in Nanjing (Disitamb Vedotin ,pyrotinib)
Not yet recruiting
- Breast Cancer
- Disitamb Vedotin ,pyrotinib
-
Nanjing, Jiangsu, ChinaJiangsu Provincial People's Hospital
Aug 18, 2023
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48 Trial in Guanzhou (RC48+Tislelizumab+carboplatin,
Not yet recruiting
- Non Small Cell Lung Cancer
- +3 more
- RC48+Tislelizumab+carboplatin
- +2 more
-
Guanzhou, ChinaSunYat-senU
May 5, 2023
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate
Recruiting
- Aggressive Non-Hodgkin Lymphoma
- +8 more
- Polatuzumab Vedotin
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 26, 2023
Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma Trial in United States (brentuximab vedotin)
Terminated
- Hodgkin Lymphoma
- +2 more
- brentuximab vedotin
-
Anaheim, California
- +18 more
Dec 6, 2022
Cutaneous T-cell Lymphoma Retreated With Brentuximab Vedotin
Not yet recruiting
- T-Cell Lymphoma
- No intervention
-
Bordeaux, France
- +10 more
May 24, 2023
RC48-ADC in Breast Cancer
Not yet recruiting
- Breast Cancer
- Disitamab vedotin
- (no location specified)
Apr 30, 2023
Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Richter's Transformation
- Glofitamab
- +4 more
-
Boston, Massachusetts
- +1 more
Sep 12, 2023
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic
Recruiting
- Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
- +3 more
- Cabozantinib S-malate
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Aug 8, 2022
Breast Cancer Trial in Xi'an (Disitamab Vedotin plus pyrotinib or naratinib)
Not yet recruiting
- Breast Cancer
- Disitamab Vedotin plus pyrotinib or naratinib
-
Xi'an, Shaanxi, ChinaXi'an International Medical Center Hospital
Aug 27, 2023
Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer Trial in Kansas City (Enfortumab vedotin)
Recruiting
- Pancreatic Ductal Adenocarcinoma
- +2 more
- Enfortumab vedotin
-
Kansas City, KansasUniversity of Kansas Cancer Center
Jun 23, 2023
Gastric Cancer Trial (Disitamab Vedotin combined with Sintilimab)
Not yet recruiting
- Gastric Cancer
- Disitamab Vedotin combined with Sintilimab
- (no location specified)
Jul 2, 2023
Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter Trial in
Recruiting
- Urothelial Cancer
- +3 more
- Sacituzumab Govitecan (SG)
- Enfortumab vedotin-ejfv (EV)
-
Boston, MassachusettsDana Farber Cancer Institute
Sep 28, 2022
Advanced Classical Hodgkin's Lymphoma in Brazil Treated With
Not yet recruiting
- Hodgkin Lymphoma
- No Intervention
-
Salvador, Bahia, Brazil
- +5 more
Oct 23, 2023